Associations between the expression of SCCA, MTA1, P16, Ki‑67 and the infection of high‑risk HPV in cervical lesions

Han,Cuina; Zhao,Fangfei; Wan,Chongyang; He,Yanfang; Chen,Yan

doi:10.3892/ol.2020.11634

Associations between the expression of SCCA, MTA1, P16, Ki‑67 and the infection of high‑risk HPV in cervical lesions

Authors:
- Cuina Han
- Fangfei Zhao
- Chongyang Wan
- Yanfang He
- Yan Chen
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, North China University of Science and Technology Affiliated Hospital, Tangshan, Hebei 063000, P.R. China
Published online on: May 18, 2020 https://doi.org/10.3892/ol.2020.11634
Pages: 884-892
Copyright: © Han et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The application of detection technologies for human papillomavirus (HPV) has increased the resection rate for cervical intraepithelial neoplasia and early cervical cancer types. However, a large number of patients still present with advanced cervical cancer upon diagnosis. Therefore, to find a marker for the early diagnosis of cervical cancer, the present study investigated the expression profiles of squamous cell carcinoma antigen (SCCA), tumor metastasis related factor‑1 (MTA1), the multiple tumor suppressor gene P16, and the nucleus‑associated antigen Ki‑67 in cervical lesions, and evaluated the association between the four proteins and the infection of high‑risk (HR)‑HPV in cervical lesions. The rate of SCCA expression gradually increased with the progression of cervical lesions, but the increase in SCCA expression levels from low‑grade squamous intraepithelial lesions (LSIL) to high‑grade squamous intraepithelial lesions was not significant (P=0.197). The positive rate of MTA1 expression gradually increased with the development of cervical lesions, but the increase from chronic cervicitis to LSIL was not significant (P=0.258). The positive rates of P16 and Ki‑67 expression exhibited significant increasing trends with the progression of cervical lesions. The expression ratio of SCCA between HR‑HPV infection and non‑infection groups was not statistically significant (P=0.38), but the expression ratios of MTA1, P16 and Ki‑67 between HR‑HPV infection and non‑infection groups were statistically significant (P<0.05). These results demonstrated that the expression of SCCA, MTA1, P16 and Ki‑67 increased gradually with the severity of cervical lesions. In addition, there was a positive association between the expression levels of MTA1, P16 and Ki‑67 and the infection of HR‑HPV in cervical lesions. Therefore, SCCA, MTA1, P16 and Ki‑67 may be used to enhance the diagnostic accuracy for cervical lesions.

View Figures

View References

1	Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J and Bray F: Estimates of incidence and mortality of cervical cancer in 2018: A worldwide analysis. Lancet Glob Health. 8:e191–e203. 2020. View Article : Google Scholar : PubMed/NCBI
2	Plummer M, Peto J and Franceschi S; International Collaboration of Epidemiological Studies of Cervical Cancer, : Time since first sexual intercourse and the risk of cervical cancer. Int J Cancer. 130:2638–2644. 2012. View Article : Google Scholar : PubMed/NCBI
3	Shrestha AD, Neupane D, Vedsted P and Kallestrup P: Cervical cancer prevalence, incidence and mortality in low and middle income countries: A systematic review. Asian Pac J Cancer Prev. 19:319–324. 2018.PubMed/NCBI
4	Arbyn M, Snijders PJ, Meijer CJ, Berkhof J, Cuschieri K, Kocjan BJ and Poljak M: Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening? Clin Microbiol Infect. 21:817–826. 2015. View Article : Google Scholar : PubMed/NCBI
5	Wright TC, Stoler MH, Behrens CM, Sharma A, Zhang G and Wright TL: Primary cervical cancer screening with human papillomavirus: End of study results from the ATHENA study using HPV as the first-line screening test. Gynecol Oncol. 136:189–197. 2015. View Article : Google Scholar : PubMed/NCBI
6	Dasari S, Wudayagiri R and Valluru L: Cervical cancer: Biomarkers for diagnosis and treatment. Clin Chim Acta. 445:7–11. 2015. View Article : Google Scholar : PubMed/NCBI
7	Pozzan C, Cardin R, Piciocchi M, Cazzagon N, Maddalo G, Vanin V, Giacomin A, Pontisso P, Cillo U and Farinati F: Diagnostic and prognostic role of SCCA-IgM serum levels in hepatocellular carcinoma (HCC). J Gastroenterol Hepatol. 29:1637–1644. 2014. View Article : Google Scholar : PubMed/NCBI
8	Maddalo G, Fassan M, Cardin R, Piciocchi M, Marafatto F, Rugge M, Zaninotto G, Pozzan C, Castoro C, Ruol A, et al: Squamous cellular carcinoma antigen serum determination as a biomarker of barrett esophagus and esophageal cancer. J Clin Gastroenterol. 52:401–406. 2018. View Article : Google Scholar : PubMed/NCBI
9	Chechlinska M, Kowalewska M, Brzoska-Wojtowicz E, Radziszewski J, Ptaszynski K, Rys J, Kaminska J and Nowak R: Squamous cell carcinoma antigen 1 and 2 expression in cultured normal peripheral blood mononuclear cells and in vulvar squamous cell carcinoma. Tumor Biol. 31:559–567. 2010. View Article : Google Scholar
10	El-Rachkidy RG, Young HS, Griffiths CE and Camp RD: Humoral autoimmune responses to the squamous cell carcinoma antigen protein family in psoriasis. J Invest Dermatol. 128:2219–2224. 2008. View Article : Google Scholar : PubMed/NCBI
11	Jeong BK, Choi DH, Huh SJ, Park W, Bae DS and Kim BG: The role of squamous cell carcinoma antigen as a prognostic and predictive factor in carcinoma of uterine cervix. Radiat Oncol J. 29:191–198. 2011. View Article : Google Scholar : PubMed/NCBI
12	Shimura K. Mabuchi S, Yokoi T, Sasano T, Sawada K, Hamasaki T and Kimura T: Utility of serum squamous cell carcinoma antigen levels at the time of recurrent cervical cancer diagnosis in determining the optimal treatment choice. J Gynecol Oncol. 24:321–329. 2013. View Article : Google Scholar : PubMed/NCBI
13	Kim BG: Squamous cell carcinoma antigen in cervical cancer and beyond. J Gynecol Oncol. 24:291–292. 2013. View Article : Google Scholar : PubMed/NCBI
14	Sen N, Gui B and Kumar R: Role of MTA1 in cancer progression and metastasis. Cancer Metastasis Rev. 33:879–889. 2014. View Article : Google Scholar : PubMed/NCBI
15	Yi S, Guangqi H and Guoli H: The association of the expression of MTA1, NM23H1 with the invasion, metastasis of ovarian carcinoma. Chin Med Sci J. 18:87–92. 2003.PubMed/NCBI
16	Guddeti RK, Bali P, Karyala P and Pakala SB: MTA1 coregulator regulates LDHA expression and function in breast cancer. Biochem Biophys Res Commun. 520:54–59. 2019. View Article : Google Scholar : PubMed/NCBI
17	Bilikezi·Aikemu F, Min L, Xiumei Z, Junling G, Danjin G and Qi: Expression and significance of MTA1, MMP-2, MMP-7 in cervical cancer. Chin J Mod Med. 23:51–54. 2013.
18	Dannenmann C, Shabani N, Friese K, Jeschke U, Mylonas I and Brüning A: The metastasis-associated gene MTA1 is upregulated in advanced ovarian cancer, represses ERβ, and enhances expression of oncogenic cytokine GRO. Cancer Biol Ther. 7:1460–1467. 2008. View Article : Google Scholar : PubMed/NCBI
19	Rao Y, Wang H, Fan L and Chen G: Silencing MTA1 by RNAi reverses adhesion, migration and invasiveness of cervical cancer cells (SiHa) via altered expression of p53, and E-cadherin/β-catenin complex. J Huazhong Univ Sci Technolog Med Sci. 31:1–9. 2011. View Article : Google Scholar : PubMed/NCBI
20	Scheffner M, Werness BA, Huibregtse JM, Levine AJ and Howley PM: The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 63:1129–1136. 1990. View Article : Google Scholar : PubMed/NCBI
21	Moody CA and Laimins LA: Human papillomavirus oncoproteins: Pathways to transformation. Nat Rev Cancer. 10:550–560. 2010. View Article : Google Scholar : PubMed/NCBI
22	Pan FP, Zhou HK, Bu HQ, Chen ZQ, Zhang H, Xu LP, Tang J, Yu QY, Chu YQ, Pan J, et al: Emodin enhances the demethylation by 5-Aza-CdR of pancreatic cancer cell tumor-suppressor genes P16, RASSF1A and ppENK. Oncol Rep. 35:1941–1949. 2016. View Article : Google Scholar : PubMed/NCBI
23	Bleotu C, Botezatu A, Goia CD, Socolov D, Corniţescu F, Teleman S, Huică I, Iancu I and Anton G: P16INK4A-A possible marker in HPV persistence screening. Roum Arch Microbiol Immunol. 68:183–189. 2009.PubMed/NCBI
24	Sun X and Kaufman PD: Ki-67: More than a proliferation marker. Chromosoma. 127:175–186. 2018. View Article : Google Scholar : PubMed/NCBI
25	Kimura M, Matsumoto T, Morizane T, Sonoue H, Ogishima D and Kinoshita K: Histopathological study of the spreading neoplastic cells in cervical glands and surface epithelia in cervical intra-epithelial neoplasia and microinvasive squamous cell carcinoma: Ki-67 immunostaining is a useful marker for pathological diagnosis from the gland involvement site. Pathol Int. 56:428–433. 2006. View Article : Google Scholar : PubMed/NCBI
26	Carreras R, Alameda F, Mancebo G, García-Moreno P, Mariñoso ML, Costa C, Fusté P, Baró T and Serrano S: A study of Ki-67, c-erbB2 and cyclin D-1 expression in CIN-I, CIN-III and squamous cell carcinoma of the cervix. Histol Histopathol. 22:587–592. 2007.PubMed/NCBI
27	Yang D, Xu Q and Mao Q: Expression of P16, Ki67 and HPV16/18 in cervical lesions and their clinical implications. Int J Pathol Clin Med. 32:211–215. 2012.
28	Clarke MA, Cheung LC, Castle PE, Schiffman M, Tokugawa D, Poitras N, Lorey T, Kinney W and Wentzensen N: Five-year risk of cervical precancer following p16/ki-67 dual-stain triage of HPV-positive women. JAMA Oncol. 5:181–186. 2019. View Article : Google Scholar : PubMed/NCBI
29	Wentzensen N, Clarke MA, Bremer R, Poitras N, Tokugawa D, Goldhoff PE, Castle PE, Schiffman M, Kingery JD, Grewal KK, et al: Clinical evaluation of human papillomavirus screening with p16/ki-67 dual stain triage in a large organized cervical cancer screening program. JAMA Intern Med. 179:881–888. 2019. View Article : Google Scholar : PubMed/NCBI
30	Zhong P, Li J, Gu Y, Liu Y, Wang A, Sun Y and Lu L: P16 and Ki-67 expression improves the diagnostic accuracy of cervical lesions but not predict persistent high risk human papillomavirus infection with CIN1. Int J Clin Exp Pathol. 8:2979–2986. 2015.PubMed/NCBI
31	Pesic A, Krings A, Hempel M, Preyer R, Chatzistamatiou K, Agorastos T and Kaufmann AM: CIN2+ detection of the HPV DNA array genotyping assay in comparison with the cobas 4800 HPV test and cytology. Virol J. 16:922019. View Article : Google Scholar : PubMed/NCBI
32	Tang Z, Xu Y, Song N, Zou D, Liao Y, Li Q and Pan C: A comparison of the MeltPro^® HPV test with the Cobas^® HPV test for detecting and genotyping 14 high-risk human papillomavirus types. Arch Virol. 163:725–730. 2018. View Article : Google Scholar : PubMed/NCBI
33	Brusselaers N, Shrestha S, van de Wijgert J and Verstraelen H: Vaginal dysbiosis and the risk of human papillomavirus and cervical cancer: Systematic review and meta-analysis. Am J Obstet Gynecol. 221:9–18. 2019. View Article : Google Scholar : PubMed/NCBI
34	Melnikow J, Henderson JT, Burda BU, Senger CA, Durbin SS and Weyrich MS: Screening for cervical cancer with high-risk human papillomavirus testing. JAMA. 320:687–705. 2018. View Article : Google Scholar : PubMed/NCBI
35	Kjær SK, Munk C, Junge J and Iftner T: Carcinogenic HPV prevalence and age-specific type distribution in 40,382 women with normal cervical cytology, ASCUS/LSIL, HSIL, or cervical cancer: What is the potential for prevention? Cancer Causes Control. 25:179–189. 2014. View Article : Google Scholar : PubMed/NCBI
36	Song SH, Park HM, Eom DW, Lee JK, Lee NW, Kim AR, Hur JY, Lee KW, Park YK and Saw HS: The expression of p16 (INK4a) and Ki-67 in relation to high-risk human papilloma viral load and residual disease after conization with positive margins. Int J Gynecol Cancer. 17:858–867. 2007. View Article : Google Scholar : PubMed/NCBI